Despite the benefits of SGLT2-i and GLP1-RA in chronic kidney disease, the existing data regarding their efficacy in the kidney transplant population remain sparse, while concerns about potential adverse events may limit their prescription. The gene discussed is GLP1R; the disease is chronic kidney disease.